2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Transfusion, Non-Biological Therapies, Devices, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Computer Vision, Machine Learning, Biological Processes, Genomics, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Quality of Care, Systems-Based Hematology, Value, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Infectious Diseases, Viral, Bacterial, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Embryo/Fetus, Pediatric, Pregnant, Young Adult
PAPER

1174 Effect of α‐thalassemia on HbSC sickle cell disease: An NIH cohort study

Nancy Asomaning, MS, CCRC, Rialnat A Lawal, MD, PhD2, Anna Conrey3, Swee Lay Thein, MD, DSc4
1 National Institutes of Health, Bethesda, Maryland, United States
2 National Institutes of Health, Bethesda, Maryland, United States
3 National Institutes of Health, Bethesda, Maryland, United States
4 National Institutes of Health, Bethesda, Maryland, United States

Hemoglobin SC (HbSC) is the second most common form of sickle cell disease (SCD), accounting for 25-30% of cases worldwide. Although generally considered a milder form of SCD, its clinical course can be highly variable. Genetic modifiers, including coinherited a-thalassemia, contribute to this variability. In people of Sub-Saharan African descent, α-thalassemia is most commonly caused by the 3.7-kb α-deletion, which reduces intracellular a-globin chains, which are positively charged. Because b-globin compete for a-globin binding, with affinity following the order bA > bS > bC, reduced a-globin chain availability in α-thalassemia is expected to preferentially decrease HbC in HbSC disease (and HbS in HbAS / HbSS), as a potential phenotypic modifier. We conducted a retrospective cross-sectional study to assess the role of alpha thalassemia in NIH patients with the HbSC genotype.

 

Data from 139 HbSC subjects enrolled between 2001-2026 on IRB-approved protocols NCT00011648 and NCT00081523 were included. All subjects are at least 18 years old and provided informed consent. Participants were not transfused at the time of sample collection. Alpha-globin genotyping was performed using droplet digital polymerase chain reaction and hemoglobin fractions were obtained using HPLC electrophoresis. Kruskal-Wallis test was used for group comparisons. Continuous variables were summarized as median (range) and categorical variables were summarized as counts and percentages. Statistical analysis was performed using R (version 2026.07.1).

 

The average age of subjects was 42 years (range: 18-86), 77 (55%) were females, 135 (97%) Black/African American, and 25 (18%) on hydroxyurea (HU).  Our dataset consisted of 95 subjects with available alpha-globin data: 6 (6.3%) -α/-α, 26 (27.3%)-α/αα, 61 (64.2%) αα/αα, and 2 (2.10%) ααα/αα. The 2 subjects with ααα/αα were excluded from the analysis because of the small sample size. Of these 93 subjects, the median (range) SC ratio was 1.040 (0.944–1.255), HbA2 was 3.7% (2.5-5.0), mean corpuscular volume (MCV(fL)) was 78.1(58.7–119.3), mean corpuscular hemoglobin (MCH(pg)) was 28.1(20.9–42.9), and ferritin (ng/mL) was 136 (7.0–2128.0). Although median HbS (%) for coinherited α-thalassemia (-α/-α and -α/αα) was lower compared to wild type (αα/αα), (47.3% n=32 vs 48.0% n=61, p=0.416), it was not significant. Coinherited α-thalassemia, had significantly lower MCV (73.90 vs 81.50), MCH (26.10 vs 29.75), platelet count (K/mcL, 206 vs 287), and absolute lymphocytes (K/mcL, 1.75 vs 2.58), but higher RBC count (4.23 vs 3.83). Only the associations with MCV and MCH remained significant after correction for multiple testing (p<0.001).

The S:C ratio decreased with decreasing a-globin copy number: median (range) 1.044 (0.949-1.255) for αα/αα; 1.035 (0.949-1.221) for -α/αα; 1.021 (0.944-1.043) for -α/-α. Although this trend was not statistically significant (Kruskal-Wallis P = 0.102), it was contrary to what we expected. 

Stratifying by S:C ratio (≤1 vs >1), among the 16 (17%) subjects with SC ≤1, genotype distribution was 1 (6.2%) -α/-α, 7 (43.8%) -α/αα, and 8 (50.0%) αα/αα, with median (range) S:C ratio of 0.944, 0.983 (0.949-1), and 0.960 (0.948-1), respectively (p=0.241). Among the 77 participants (83%) with S:C >1, distribution was 5 (6.5%) -α/-α, 19 (24.7%) -α/αα, and 53 (68.8%) αα/αα, with median (range) S:C of 1.028 (1.009-1.043), 1.042 (1.009-1.221), 1.049 (1.011-1.255), respectively (p=0.0911). A greater proportion of patients with single deletion (43.7% vs 24.7%) and double deletion (7.7% vs 6.5%) genotypes had S:C ratio ≤1.

Overall, about 33% of this cohort carried a-thalassemia, consistent with the expected 20-35% reported in the literature. Our HbSC SCD cohort showed slightly more HbS than HbC (S:C ratio: 1.040), similar to prior literature. However, contrary to expectation, we did not observe a consistent increase in HbS% relative to the more positively charged HbC despite α-globin chain loss; instead, the S:C ratio trended downward with decreasing α-globin copy number. Notably, 17% of the participants had S:C ≤1, and about half of these had coinherited α -thalassemia. These findings suggest the relationship between α-globin availability and β-globin variant selection in HbSC disease may be more complex than predicted by charge-based affinity alone, warranting further mechanistic investigation.

 

Nancy Asomaning, MS, CCRC: No relevant conflicts of interest to declare.